Fumery M, Filippi J, Abitbol V, et al. - Researchers conducted the study for analyzing the real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis (UC). All consecutive patients with active UC treated with ustekinumab in a GETAID centre were involved from January to September 2019. At week 52, patients were evaluated. The sample consisted of 103 patients with UC (62 men; mean age: 41.2 ± 16.2 years; 52% pancolitis E3) with an insufficient response to immunosuppressants, anti-TNFs and/or vedolizumab. At week 52, 45 (44%) patients had stopped ustekinumab mainly due to lack of effectiveness (n = 41). At week 52, the overall steroid-free clinical remission rate was 32%, with 71% having subscores of null for rectal bleeding and stool frequency. After 52 weeks, ustekinumab was still being used to treat more than half of patients with refractory UC, and one-third were in steroid-free clinical remission.